Madrigal Pharmaceuticals Reveals Inducement Award Grants in Compliance with Nasdaq Listing Rule 5635(c)(4)

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Aug 21 2025

0mins

Source: Globenewswire

Equity Awards Announcement: Madrigal Pharmaceuticals granted equity awards to 11 new non-executive employees on August 15, 2025, as part of its 2025 Inducement Plan.
Details of the Equity Awards: The awards included a total of 6,940 time-based restricted stock units that will vest in four equal installments over four years, contingent upon continued employment.
Company Focus: Madrigal Pharmaceuticals specializes in developing therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with significant unmet medical needs.
Key Product Information: The company's medication, Rezdiffra, is the first FDA and European Commission approved treatment for MASH with moderate to advanced fibrosis and is currently undergoing a Phase 3 trial for compensated MASH cirrhosis.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for NVDA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy NVDA?

Get Started Free